Lagevrio (molnupiravir) Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)

ChiCTR2200060010: Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations

Not yet recruiting

100

Molnupiravir ;Paxlovid

Beijing Ditan Hospital Capital Medical University; Beijing Ditan Hospital Capital Medical University, Research project of Beijing Ditan Hospital, Capital Medical University

Novel coronavirus pneumonia (COVID-19) at high risk of severe disease

ChiCTR2200059796: A randomized-controlled study of molnupiravir in COVID-19 infection

Recruiting

126

Molnupiravir ;No

The First Affiliated Hospital of Naval Medical University; Changhai Hospital, self-funded

SARS-CoV-2 infection

Molnupiravir in severe fever with thrombocytopenia syndrome (SFTS), ChiCTR2400082172: a multi-center, randomized controlled study

Not yet recruiting

300

Oral molnupiravir 800 mg q12h for 5 days; Oral placebo, four capsules q12h for 5 days

Juxian People's Hospital; Juxian People's Hospital, 2023 National Key Research and Development Program of China, 2023YFC2308800

severe fever with thrombocytopenia syndrome

2021-000904-39: MK4482-013 Phase 3 Study for Prevention of COVID-19 in Adults Estudio de fase 3 de MK-4482-013 para la prevención de la COVID-19 en adultos

Ongoing

1500

Europe, RoW

Molnupiravir, MK-4482, Capsule

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Prophylaxis of COVID-19 Profilaxis de la COVID-19 en adultos, Prevention of COVID-19 Prevención de la COVID-19, Diseases [C] - Virus Diseases [C02]

RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

	Efficacy and safety data from RECOVERY trial in COVID-19
	Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19

Recruiting

70000

Europe, RoW

Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone

University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab

Severe Acute Respiratory Syndrome

06/26

06/36

CoTeT, NCT05459532: A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa

Recruiting

4000

RoW

Molnupiravir 200 mg

University of Witwatersrand, South Africa, Bill and Melinda Gates Foundation

COVID-19

07/24

07/27

MOVe-NOW, NCT06667700: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Recruiting

3082

Europe, US, RoW

Molnupiravir, MK-4482, LAGEVRIO®, Placebo

Merck Sharp & Dohme LLC

Coronavirus Disease (COVID-19)

01/31

MK-4482-017, NCT05559905: Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants

Completed

116

Europe

Molnupiravir, MK-4482, Placebo, RSV A Memphis 37b

Merck Sharp & Dohme LLC

Respiratory Syncytial Virus

04/23

06/23

ARSYNAL-FC, NCT06488300: Assessing Antiviral Treatments in Early Symptomatic RSV

Not yet recruiting

1000

RoW

Ribavirin, Molnupiravir, Favipiravir

University of Oxford

Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human

01/27

PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19

Recruiting

3800

RoW

Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir

University of Oxford

COVID-19

01/27

AD ASTRA, NCT05648448: A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting

3000

RoW

Oseltamivir, Favipiravir, Zanamivir, Baloxavir, Molnupiravir, Peramivir, Laninamivir, Oseltamivir and Baloxavir, Oseltamivir and Favipiravir, Favipiravir and Baloxavir

University of Oxford

Influenza, Influenza, Human

01/27

ADAPT, NCT06551844: Adaptive Dengue Antiviral Platform Trial

Not yet recruiting

500

RoW

Molnupiravir 400 mg, Molnupiravir STELLA 400mg, VIS513 (a monoclonal antibody), Dengue monoclonal antibody (Dengue mAb/ Dv Mab)

Oxford University Clinical Research Unit, Vietnam, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Dengue, Antiviral Drugs

12/29

12/30

NCT04746183: AGILE (Early Phase Platform Trial for COVID-19)

Jan 2022 - Jun 2022 : Data from AGILE trial for COVID-19

Active, not recruiting

1/2

600

Europe, RoW

CST-2: EIDD-2801, MK-4482, Molnupiravir, CST-2: Placebo, Placebo, Nitazoxanide, VIR-7832, VIR-7831, Sotrovimab, CST-5: Placebo, Favipiravir, Lagevrio, Paxlovid, nirmatrelvir and ritonavir

University of Liverpool, University of Southampton, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Cambridge

Covid19

07/25

MK-4482-011, NCT06615869: A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants

Completed

Molnupiravir, MK-4482, MOV, LAGEVRIO, EIDD-2801

Merck Sharp & Dohme LLC

Healthy

02/23

03/23

MK-4482-003, NCT05386758: A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment

Completed

Molnupiravir, MK-4482; MOV; EIDD-2801

Merck Sharp & Dohme LLC

Renal Impairment

02/23

03/23

NCT06816030: A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

Completed

RoW

MK-4482

Merck Sharp & Dohme LLC

Healthy

08/23

NCT05818124: Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)

Completed

162

Europe

Molnupiravir, MK-4482, Placebo molnupiravir, Placebo oseltamivir, Oseltamivir, Influenza A Virus

Merck Sharp & Dohme LLC

Influenza Infection

06/24

NCT05412173: Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

Completed

N/A

RoW

Molnupiravir

Valenta Pharm JSC

Viral Infection, COVID-19

05/22

06/22

NCT06223932: Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.

Active, not recruiting

N/A

2600

RoW

Molnupiravir

Serap Yavuz, MDX Klinik Araştırma Egitim ve Danismanlik Ltd. Sti.

COVID-19, SARS-CoV-2 Infection

02/24

myRECOVER, NCT05638919: Real World COVID-19 Antiviral Effectiveness Research

Recruiting

N/A

660

RoW

Oral Antiviral, Paxlovid, Lagevrio

Clinical Research Centre, Malaysia

COVID-19

07/23

ESOA-19, NCT05894603: Effectiveness and Safety of New Oral Antivirals for COVID-19

Active, not recruiting

N/A

211

Europe

Nirmatrelvir/ritonavir, Paxlovid, Molnupiravir, Lagevrio

Universidade do Porto, Faculty of Medicine (FMUP), Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS), Rede de Investigação em Saúde (RISE), Laboratório Associado

COVID-19

01/24

06/24

COVID-PR, NCT05013632: COVID-19 International Drug Pregnancy Registry

Recruiting

N/A

2000

Antiviral Agents, Veklury (remdesivir), Lagevrio (molnupiravir), Monoclonal antibody, REGEN-COV (casirivimab/imdevimab), Xevudy (sotrovimab)

Pregistry

Covid19

09/27

TURN-COVID, NCT05195060: Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

Recruiting

N/A

1000

Europe

casirivimab with imdevimab, REGEN-COV, sotrovimab, Xevudy, molnupiravir, Lagevrio

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

COVID-19

06/24



	Diseases Companies Products Productz Mechanisms of Action Sites